Last reviewed · How we verify
placebo, carboplatin, etoposide，or Topotecan
placebo, carboplatin, etoposide，or Topotecan is a platinum-based chemotherapy Small molecule drug developed by Jiangsu Simcere Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Advanced ovarian cancer, Small cell lung cancer, Non-small cell lung cancer. Also known as: placebo plus chemotherapy.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Advanced ovarian cancer, Small cell lung cancer, Non-small cell lung cancer.
At a glance
| Generic name | placebo, carboplatin, etoposide，or Topotecan |
|---|---|
| Also known as | placebo plus chemotherapy |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin is a second-generation platinum-based chemotherapy drug that works by forming platinum-DNA adducts, which interfere with DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the formation of platinum-DNA adducts that trigger apoptosis and inhibit cell cycle progression.
Approved indications
- Advanced ovarian cancer
- Small cell lung cancer
- Non-small cell lung cancer
- Testicular cancer
- Urothelial cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo, carboplatin, etoposide，or Topotecan CI brief — competitive landscape report
- placebo, carboplatin, etoposide，or Topotecan updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about placebo, carboplatin, etoposide，or Topotecan
What is placebo, carboplatin, etoposide，or Topotecan?
How does placebo, carboplatin, etoposide，or Topotecan work?
What is placebo, carboplatin, etoposide，or Topotecan used for?
Who makes placebo, carboplatin, etoposide，or Topotecan?
Is placebo, carboplatin, etoposide，or Topotecan also known as anything else?
What drug class is placebo, carboplatin, etoposide，or Topotecan in?
What development phase is placebo, carboplatin, etoposide，or Topotecan in?
What are the side effects of placebo, carboplatin, etoposide，or Topotecan?
What does placebo, carboplatin, etoposide，or Topotecan target?
Related
- Drug class: All platinum-based chemotherapy drugs
- Target: All drugs targeting DNA
- Manufacturer: Jiangsu Simcere Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced ovarian cancer
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Non-small cell lung cancer
- Also known as: placebo plus chemotherapy
- Compare: placebo, carboplatin, etoposide，or Topotecan vs similar drugs
- Pricing: placebo, carboplatin, etoposide，or Topotecan cost, discount & access